Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06223074 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

Study acronym: IN-DXM-EMRR
StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 3, 2025 (before its estimated February 25, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Nov 27, 2024 to Feb 25, 2026
    • Study completion date: Feb 5, 2025 to Jul 5, 2026
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis
Trial Details
NCT Number NCT06223074
Lead Sponsor Universidad Nacional Autonoma de Mexico
Collaborators: Instituto Nacional de Neurología y Neurocirugía
Conditions
(from sponsor)		 Multiple Sclerosis Relapsing Remitting, Treatment
Related terms Multiple Sclerosis, Relapsing-Remitting
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov